Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients
Imunon reports early Phase 2 data showing lower residual disease and higher ctDNA clearance with IMNN-001 in ovarian cancer.
Imunon's cancer medicine is showing good early test results, meaning sick patients' tumors are shrinking more than expected. When a company reports their medicine is working better, it hints they might be on track to help people and make money, so it's worth watching for bigger test updates.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.